Apaf-1 protein deficiency occurs in human leukaemic blasts and confers resistance to cytochrome-c-dependent apoptosis. Demethylation treatment with 5-aza-2 0 -deoxycytidine (5aza2dc) increased the sensitivity of the K562 leukaemic cell line to UV light-induced apoptosis in association with increased Apaf-1 protein levels. There was no correlation between Apaf-1 protein expression and Apaf-1 mRNA levels after the demethylation treatment. Methylation-specific polymerase chain reaction was used to show that the methylation can occur within the Apaf-1 promoter region in leukaemic blasts. Apaf-1 DNA methylation was demonstrated in acute myeloid leukaemia, chronic myeloid leukaemia and acute lymphoid leukaemia, suggesting that it is not specific to a particular leukaemia subtype. Apaf-1 protein expression did not correlate with Apaf-1 mRNA levels in human leukaemic blasts. Some leukaemic cells expressed high levels of Apaf-1 mRNA but low levels of Apaf-1 protein. This study suggests that Apaf-1 DNA promoter methylation might contribute to the inactivation of Apaf-1 expression. However, Apaf-1 protein levels might also be controlled at post-transcription level.
DNA methylation, a covalent modification of the C5 position of cytosine, participates in cellular differentiation, cancer, ageing and autoimmunity (Li et al., 1992; Laird and Jaenisch, 1994; Chitnis et al., 2000; Lopatina et al., 2002) . CpG-rich sequences in the promoters of housekeeping genes are generally protected from methylation. Aberrant CpG island hypermethylation in cancer is associated with transcriptional silencing of gene expression. Current evidence suggests that it plays an important role as an alternative mechanism for tumour suppressor gene inactivation (Baylin and Herman, 2000; Feinberg, 2001; Rountree et al., 2001) . Demethylation treatment sensitizes cancer cells to chemo-or immunotherapy-induced apoptosis (Fulda et al., 2001; Soengas et al., 2001; van Noesel et al., 2002) .
Apaf-1 plays an important role in the induction of apoptosis (Zou et al., 1997) . During DNA damaging stimuli-induced apoptosis, cytochrome c is released from mitochondria. Together with dATP/ATP, cytochrome c initiates formation of an 'apoptosome' consisting of Apaf-1 oligomers. The Apaf-1 apoptosome recruits and activates caspase-9, which in turn activates the executioner caspases, caspase-3 and -7 (Li et al., 1997; Zou et al., 1997) . Deficiency in Apaf-1 protein confers resistance to cytochrome-2, c-dependent apoptosis in a variety of tumour and leukaemic cells (Perkins et al., 1998; Soengas et al., 1999; (Fu et al., 2001; Jia et al., 2001b; Wolf et al., 2001) . Upregulation of Apaf-1 protein levels by either gene transfer or demethylation treatment increases the sensitivity of cells to cytochrome-c-dependent apoptosis (Shinoura et al., 2001; Jia et al., 2001b; Soengas et al., 2001) . The mechanism leading to Apaf-1 deficiency and its link with tumorigenesis are unclear. It has been reported that the inactivated Apaf-1 gene in malignant melanoma is switched off, instead of being completely lost or mutated (Soengas et al., 2001) . The switch may involve DNA methylation and the removal of acetyl groups from the histone proteins that bundle up DNA into the compressed form seen in the nucleus (Jones, 2001) . Apaf-1 gene can be turned back on by treating cultured melanoma cells with inhibitors of DNA methylation or histone deacetylation. This occurs even though Apaf-1 DNA methylation was not detected in the promoter region of Apaf-1 in melanoma cells. It has been suggested that a transactivating regulator or enhancer of Apaf-1 gene probably is involved in methylation. An alternative regulatory element outside the Apaf-1 promoter might contribute to such changes (Soengas et al., 2001) .
This study examined the role of Apaf-1 methylation in leukaemia using polymerase chain reaction (PCR)-based technique to determine the potential role in leukaemiagenesis. The cell lines used in this study were: K562 (human chronic myeloid leukaemia (CML)), CEM (human T-acute lymphoid leukaemia (ALL)), CEM/ VLB 100 (the vinblastine-resistant subclone of CEM), Raji (human Burkitt's lymphoma), KG1a (human acute myeloid leukaemia (AML)) and J-82 (human bladder cancer). It has previously been reported that K562 cells are resistant to most of DNA damaging agents, such as UV light- (Jia et al., 2001b; Fu et al., 2001) , etoposide- (Jia et al., 2001a) and daunorubicin- (Liu et al., 2002) induced apoptosis. This resistance is at least partly because of the lower level of the functional Apaf-1 (Jia et al., 2001b; Fu et al., 2001) . To investigate whether the Apaf-1 protein deficiency is associated with Apaf-1 DNA methylation, the K562 cell line was treated with the demethylation drug 5aza2dc at different doses (0.1, 0.2 and 0.3 mm) for 4 days. Cells treated with 5aza2dc significantly increased their sensitivity to UV lightinduced apoptosis at both 4 and 6 h compared with nondemethylated K562 cells (Figure 1a) . Neither increasing the concentration of 5aza2dc from 0.1 to 0.3 mm nor extending the incubation time to 10 days was associated with an increased sensitivity to UV lightinduced apoptosis. Further increasing doses of 5aza2dc induced cell killing (data not shown). Apaf-1 protein levels were upregulated by 5aza2dc as detected by Western blotting (Figure 1b) . Similar to the apoptosis result, increasing 5aza2dc concentration did not show further increase in the levels of Apaf-1 protein. The increased sensitivity of K562 cells to apoptosis after demethylation was correlated with upregulation of Apaf-1 protein (Po0.0001, correlation). This is in agreement with the demethylation treatment that enhanced adriamycin-induced apoptosis and Apaf-1 expression in malignant melanoma (Soengas et al., 2001) . It was also observed that demethylation treatment increased the sensitivity of cells to death receptors, such as TRAILinduced apoptosis, caused by caspase-8 DNA methylation (Fulda et al., 2001; Fu et al., unpublished data) .
The mRNA levels of Apaf-1 was determined by realtime PCR. The primer sequences for RNA reaction were 5 0 -AAA AGG GGA TAG AAC CAG AGG TGG-3' (sense, À42 bp), 5 0 -TGC GGC ACC TCA AGT CTT C-3 0 (antisense, À108 bp), and probe sequence was 6FAM5'-AGT CTG GGC AGT CGG CGA CCC-3 0 TAMRA (À67 bp). Unlike Apaf-1 protein, Apaf-1 mRNA increased with concentrations of 5aza2dc. The mRNA level of Apaf-1 was upregulated after treatment with 0.1, 0.2 and 0.3 mm 5aza2dc ( Figure 1c ). Cells treated with 0.3 mm of 5aza2dc did not show any further increased Apaf-1 mRNA expression, probably owing to the toxicity of high dose of the reagent with the increased cell death. There was no statistically significant correlation between Apaf-1 mRNA and protein levels in response to demethylation reagent (P ¼ 0.4). These observations and the protein results suggested that Apaf-1 expression was, at least partially, controlled by DNA methylation.
Apaf-1 DNA methylation was examined in four leukaemia and two tumour cell lines, 17 leukaemic blasts and six normal peripheral blood samples using both conventional and real-time methylation-specific PCR (MSP). All the primers were designed between the positions bp1 and bp406 of Apaf-1 cDNA 5 0 region, the CpG-richest part of Apaf-1 promoter, as shown by the European Bioinformatics Institute (EMBL). The primer sequences for methylated reaction in both traditional and real-time MSP were 5 0 -TTT CGG GTA AAA GGG ATA GAA TTA GA-3 0 (sense, À34 bp), 5 0 -TAT AAC GCC CTT CCC CCG ACG ACG-3 0 (antisense, À173 bp), and the probe sequence was 6FAM5 0 -TTT GGG TAG TCG GCG ATT CGC G-3'TAMRA (À69 bp). Using traditional MSP, Apaf-1 methylation was detected in leukaemic cell lines, such as K562 and KG1a (two out of five, 40%) and leukaemic blasts, such as AML-6, AML-7, AML-9, ALL-1 and CML (five out of 17, 29%). Apaf-1 DNA methylation was observed in CML, AML and ALL blasts, indicating that it was not specific to the types of leukaemia. Apaf-1 DNAmethylation-positive samples were confirmed by the digestion of CGCG sites using BstU1 restriction enzyme: most of bisulphite-modified DNA-PCR fragments were digested by BstU1 (Figure 2) . The ability of real-time PCR to detect Apaf-1 methylation was determined using commercially methylated DNA as a methylation-positive control. The wild-type DNA (unmodified) and distilled water served as negative control and no template control, respectively. Cycle number less than 50 was defined as methylation. Apaf-1 DNA methylation was detected in K562 and KG1a cell lines, AML-9 and CML blasts by real-time MSP (Table 1) , as their Apaf-1 methylation was also detected by traditional MSP. However, real-time MSP failed to detect Apaf-1 methylation in AML-6, AML-7 and ALL-1 blasts (Table 1) , which was shown by traditional MSP. This result indicates that DNA methylation occurred in the Apaf-1 gene promoter region in human leukaemia and it could contribute to the reduced levels of Apaf-1 protein expression.
To further confirm whether methylation occurs in the Apaf-1 gene, Apaf-1 sequencing was performed in bisulphite-treated DNA. The K562 cell line and CML patient blasts were chosen to be sequenced because Apaf-1 DNA methylation was detected in these samples by both traditional and real-time MSP. The commercially methylated DNA served as a positive control. Cs in CpG island still maintained their original status in these three samples after bisulphite treatment, indicating that methylation occurred in CpG islands. Most of single cytosines were also maintained between sense and antisense primers in K562 and CML DNA after bisulphite modification. In addition, the cytosine in the position bp87 displayed two types of status (either methylated or unmethylated), which were found in several K562 DNA clones (Figure 3 ). This result demonstrates that methylation of Apaf-1 DNA occurred not only in CpG islands but also in single cytosines. Figure 2 Detection of Apaf-1 DNA methylation in leukaemic cells by conventional MSP. AML, CML and ALL blasts were obtained from peripheral blood from untreated patients with AML, CML or ALL and separated over a Ficoll-Hypaque gradient. The percentage of blasts in each sample was greater than 50% by morphologic assessment. DNA was extracted from leukaemic cells using the Wizard s Genomic DNA Purification Kit (Promega, Madison, USA). CpGenomet Universal Methylated DNA (Intergen, Oxford, UK) was used as a positive control in the MSP. MSP distinguishes unmethylated from methylated alleles in a given gene based on sequence changes produced after bisulphite treatment, which converts unmethylated, but not methylated, cytosines to uracil. A total of 1 mg of DNA was modified by sodium bisulphite and incubated for 16-24 h at 501C and diluted with 25-50 ml of distilled water according to the manufacture's protocol. AccuPrimet SuperMix kit (Invitrogen, Paisley, UK) was used for the traditional MSP. The reaction was set up in a 50-ml final reaction mixture consisting of 200-300 ng of modified DNA and 80 mm of each primer. Reaction started at 941C for 2 min and followed by 30 cycles of 941C for 20 s, 621C for 20 s and 681C for 20 s, one cycle of 721C for 5 min. BstU1 restriction enzyme (New England BioLabs, Hertfordshire, England, UK) was selected for the restriction analysis on MSP products. Generally, the BstU1 recognition site CGCG will remain CGCG if both C's are methylated after bisulphite treatment, but will become TGTG if unmethylated (Herman et al., 1996) . In all, 10 ml of the traditional MSP products was digested with 10 units of BstU1 in a 20-ml of reaction volume and incubated at 601C for 4 h. The PCR products, which showed methylated Apaf-1 DNA, were digested with BstU1 restriction enzyme. PCR products were electrophoresed on an 8% PAGE gel, stained with ethidium bromide and viewed by UV light. M represents pGEM-T DNA markers (Promega). P indicates a positive methylated DNA of CpGenomet. BstU1-indicates primary undigested methylated Apaf-1 DNA PCR fragments (at 140 bp) and BstU1+represents digested products of methylated DNA by BstU1 (at 85 and 55 bp) For real-time MSP, PCR reagents and conditions were same as those for traditional MSP except 50 cycles were used to amplify DNA. CT value indicates the first PCR cycle, which releases fluorescence 6FAM. All the samples have been analysed at the same time 1 Normal peripheral blood
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As mentioned above, Apaf-1 mRNA and protein showed different responses to DNA demethylation treatment. Whether DNA methylation was the major contribution to Apaf-1 protein suppression was determined. The association of Apaf-1 expression between mRNA and protein was evaluated in leukaemic cells. Apaf-1 mRNA levels from four leukaemic cell lines, eight AML and four ALL blasts were analysed by a quantitative real-time PCR. Apaf-1 RNA levels from four leukaemic cell lines showed similar levels, even though their protein levels were different. For example, Apaf-1 protein level in CEM/VLB 100 cells was three times higher than those in CEM and K562 cells (Jia et al., 2001b) . However, Apaf-1 RNA levels differed remarkably in leukaemic blasts. The ratio of the lowest RNA (0.59, AML-2) to the highest one (427.87, ALL-4) was 1 : 725 ( Figure 4a ). The Apaf-1 proteins of five leukaemia blasts displaying different RNA expression Figure 3 Bisulphite sequencing for Apaf-1 gene. Purified MSP products were cloned into pGEM-T Easy vectors, which were then transformed into JM109 competent cells (Promega, Southampton, UK). Plasmids were isolated from the positive colonies (Fu et al., 2001) . Sequencing reaction was set up with 4 ml of ABI Prism s BigDyet Terminator cycle sequencing Ready Reaction Kit v 2.0 (Applied Biosystems), 0.7 mm of T7 or Sp6 primers and 5 ng of plasmids in a 10-ml reaction system. Following 25 cycles of 961C for 10 s, 501C for 5 s and 601C for 4 min, each product was precipitated by 25 ml of 100% ethanol and 1 ml of 3 m NaAc (pH 4.6), washed once with 70% ethanol, dried for 1 min at 1001C and stored at À201C for at least 30 min. In total, 10 ml of Hi_Di Formamide (Applied Biosystems) was added to each sample and transferred to 96-well sequencing plate. After incubation at 961C for 2 min, samples were sequenced by ABI Prism s 3100 Genetic Analyzer (Applied Biosystems). Commercially methylated DNA (1), K562 DNA (2) and CML DNA (3) were modified by bisulphite. MSP products were purified, cloned and sequenced: (*) any bases except cytosine, (+) methylated cytosine, (À) unmethylated cytosine, (7) methylated or unmethylated cytosine. The sequence started from T34 and ended at A173 Figure 4 Apaf-1 expression at RNA and protein levels. (a) Apaf-1 mRNA expression: Four cell lines, eight cases of AML and four cases of ALL were used for Apaf-1 RNA study. RNA levels in these samples were quantified by relative standard curve method. K, C, V and R were K562, CEM, CEM/VLB 100 and Raji cell lines, respectively. Apaf-1 mRNA levels are represented by ratios of Apaf-1 to b-actin. (b) Apaf-1 protein expression: Apaf-1 protein was quantified by Western blot using anti-rabbit Apaf-1 polyclonal antibody (QED Bioscience Inc.) at 1 : 1000 dilution and anti-mouse b-actin monoclonal antibody (Clone AC-74, Sigma) at 1 : 5000 dilution Apaf-1 DNA methylation in human leukaemia W-N Fu et al levels were quantified by Western blotting using b-actin as an internal control (Figure 4b ). AML-2 blast showed low levels of Apaf-1 at both mRNA and protein levels. AML-3 and AML-5 displayed high Apaf-1 protein but less Apaf-1 mRNA levels. In contrast, AML-8 and ALL-4 showed high Apaf-1 mRNA, but low Apaf-1 protein expression. Statistically, there was no correlation (P ¼ 0.7) between Apaf-1 mRNA and protein expression levels (Table 2 ). These results suggest that the Apaf-1 protein level is not entirely controlled at mRNA expression level.
The evidence that the methylation in Apaf-1 gene was detected and demethylation treatment upregulated Apaf-1 expression at both mRNA and protein levels demonstrates that DNA methylation plays a role in the suppression of Apaf-1 expression in human leukaemia. It is unclear whether the control of DNA methylation on Apaf-1 protein expression is universal for all human tissues. Apaf-1 DNA methylation was neither detected in the J-82 bladder tumour cell line that showed Apaf-1 protein deficiency (Jia et al., 2001b) nor in melanoma (Soengas et al., 2001) . Apaf-1 mRNA expression in K562 cells did not correlate with its protein level. In addition, some of the leukaemia blasts showed high levels of Apaf-1 mRNA with low levels of the protein. This finding suggests the post-transcriptional regulation of Apaf-1 protein expression.
In summary, this study showed that DNA methylation occurs in the Apaf-1 gene promoter region and this methylation could partially control Apaf-1 protein levels in human leukaemic cells. Upregulation of Apaf-1 protein expression by demethylation might be a potential strategy to sensitize leukaemic cells to chemotherapy-induced apoptosis. Data of Apaf-1 expression were selected from Figure 4 . Relevant Apaf-1 levels were represented by the ratio of Apaf-1 to b-actin. Correlation between protein and mRNA levels of Apaf-1 was statistically analysed by SSPS-10 program
